Soligenix Stock Performance
| SNGX Stock | USD 3.31 0.05 1.49% |
The entity has a beta of -0.51, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Soligenix are expected to decrease at a much lower rate. During the bear market, Soligenix is likely to outperform the market. At this point, Soligenix has a negative expected return of -0.0785%. Please make sure to validate Soligenix's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Soligenix performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Soligenix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong technical and fundamental indicators, Soligenix is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (1.49) | Five Day Return (6.23) | Year To Date Return (75.66) | Ten Year Return (99.91) | All Time Return (100.00) |
Last Split Factor 1:16 | Dividend Date 2016-10-07 | Last Split Date 2024-06-06 |
1 | Soligenix Receives European Patent for Improved Production of Synthetic Hypericin | 09/03/2024 |
2 | Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - AccessWire | 09/20/2024 |
3 | SNGX Marburg Outbreak Puts Focus on Soligenix Vaccine Development | 10/03/2024 |
4 | Soligenix Invited to Present at Upcoming Investor Conferences | 10/16/2024 |
5 | Acquisition by Zeldis Jerome B of 38136 shares of Soligenix at 0.59 subject to Rule 16b-3 | 10/18/2024 |
6 | Acquisition by Lapointe Anthony Gregg of 30928 shares of Soligenix at 0.97 subject to Rule 16b-3 | 10/24/2024 |
7 | Soligenix GAAP EPS of -0.78 beats by 0.61 | 11/08/2024 |
8 | Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels | 11/14/2024 |
9 | Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma | 11/19/2024 |
| Begin Period Cash Flow | 13.4 M |
Soligenix |
Soligenix Relative Risk vs. Return Landscape
If you would invest 392.00 in Soligenix on August 26, 2024 and sell it today you would lose (61.00) from holding Soligenix or give up 15.56% of portfolio value over 90 days. Soligenix is currently does not generate positive expected returns and assumes 6.1534% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Soligenix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Soligenix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Soligenix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Soligenix, and traders can use it to determine the average amount a Soligenix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0128
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SNGX |
Estimated Market Risk
| 6.15 actual daily | 54 54% of assets are less volatile |
Expected Return
| -0.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Soligenix is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Soligenix by adding Soligenix to a well-diversified portfolio.
Soligenix Fundamentals Growth
Soligenix Stock prices reflect investors' perceptions of the future prospects and financial health of Soligenix, and Soligenix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Soligenix Stock performance.
| Return On Equity | -1.4 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (21.60) % | ||||
| Current Valuation | 669.23 K | ||||
| Shares Outstanding | 2.51 M | ||||
| Price To Earning | (1.67) X | ||||
| Price To Book | 1.40 X | ||||
| Price To Sales | 22.81 X | ||||
| Revenue | 839.36 K | ||||
| Gross Profit | 95.63 K | ||||
| EBITDA | (7.85 M) | ||||
| Net Income | (6.14 M) | ||||
| Cash And Equivalents | 20.16 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 3.49 M | ||||
| Debt To Equity | 2.44 % | ||||
| Current Ratio | 2.36 X | ||||
| Book Value Per Share | 2.59 X | ||||
| Cash Flow From Operations | (8.6 M) | ||||
| Earnings Per Share | (6.43) X | ||||
| Market Capitalization | 8.31 M | ||||
| Total Asset | 9.8 M | ||||
| Retained Earnings | (225.7 M) | ||||
| Working Capital | 3.36 M | ||||
| Current Asset | 7.15 M | ||||
| Current Liabilities | 7.41 M | ||||
About Soligenix Performance
Evaluating Soligenix's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Soligenix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Soligenix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.66) | |
| Return On Capital Employed | (2.11) | (2.01) | |
| Return On Assets | (0.63) | (0.66) | |
| Return On Equity | (2.43) | (2.31) |
Things to note about Soligenix performance evaluation
Checking the ongoing alerts about Soligenix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Soligenix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Soligenix generated a negative expected return over the last 90 days | |
| Soligenix has high historical volatility and very poor performance | |
| Soligenix has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 839.36 K. Net Loss for the year was (6.14 M) with profit before overhead, payroll, taxes, and interest of 95.63 K. | |
| Soligenix currently holds about 20.16 M in cash with (8.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Latest headline from finance.yahoo.com: Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma |
- Analyzing Soligenix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Soligenix's stock is overvalued or undervalued compared to its peers.
- Examining Soligenix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Soligenix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Soligenix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Soligenix's stock. These opinions can provide insight into Soligenix's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Soligenix Stock Analysis
When running Soligenix's price analysis, check to measure Soligenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Soligenix is operating at the current time. Most of Soligenix's value examination focuses on studying past and present price action to predict the probability of Soligenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Soligenix's price. Additionally, you may evaluate how the addition of Soligenix to your portfolios can decrease your overall portfolio volatility.